selamectin and Cat-Diseases

Since its introduction approximately seven years ago, selamectin (Stronghold/Revolution, Pfizer Inc.) has been used off-label to treat a number of ecto- and endoparasite conditions in dogs and cats. It has been used as a successful prophylactic against Dirofilaria repens and as a treatment for Aelurostrongylus abstrusus in cats. It has also been used to treat notoedric mange, infestation with the nasal mite Pneumonyssoides caninum, Cheyletiella spp. and Neotrombicula autumnalis infestations and larval Cordylobia anthropophaga infection. However, to date attempts to treat generalised canine demodicosis have not been successful. In all cases, treatment was apparently well tolerated by the host.

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Helminthiasis, Animal; Ivermectin

The monthly administration of broad-spectrum heartworm medications can effectively prevent a variety of internal and external parasitic diseases in cats. Although not every parasite can be stopped, many of the common feline parasites are susceptible to these agents. This article discusses the epidemiology and prevention strategies for those parasites that can be controlled by the administration of ivermectin, milbemycin oxime, or selamectin, either alone or in conjunction with an external parasiticide.

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Ectoparasitic Infestations; Helminths; Intestinal Diseases, Parasitic; Ivermectin; Macrolides; Mites; Phthiraptera; Siphonaptera; Ticks

For a number of reasons, several of the more 'traditional' ectoparasiticides in the small animal veterinarian's armoury have been withdrawn over the past few years. New, safer products which are long-acting and easier to apply than the conventional dips, rinses and aerosol sprays of the past have replaced them. However, relatively few such novel acaricidal preparations have become commercially available. Consequently, practitioners and researchers frequently experiment with the drugs they have at their disposal to assess their efficacy against a variety of target acarids when used at different dosages and/or via different routes of administration, compared with those recommended by the manufacturer. This paper reviews the anecdotal and peer-reviewed reports describing the use of modern acaricides in dogs and cats that have recently appeared in the veterinary literature. It should be stressed, however, that no medicine should be prescribed for extra-label use without the informed consent of the owner.

Topics: Administration, Cutaneous; Administration, Oral; Animals; Cat Diseases; Cats; Clinical Trials as Topic; Dog Diseases; Dogs; Insecticides; Ivermectin; Macrolides; Mite Infestations; Mites; Pyrazoles; Scabies; Toluidines

The past 10 years have witnessed the development of several new insecticides that have been specifically designed to exploit physiologic differences between insects and mammals. This has resulted in products that seem to have a wide margin of safety when used in dogs and cats. Compared with the more acutely toxic organophosphorous, carbamate, and heavy metal insecticides as well as with the environmental problems of bioaccumulation associated with some of the organochlorine insecticides, these newer insecticides such as fipronil, imidacloprid, selamectin, lufenuron, and nitenpyram seem to alleviate these known problems while still providing satisfactory insecticidal activity.

Topics: Animals; Benzamides; Cat Diseases; Cats; Dog Diseases; Dogs; Drug-Related Side Effects and Adverse Reactions; Imidazoles; Insecticides; Ivermectin; Neonicotinoids; Nitro Compounds; Pesticides; Pyrazoles

Topics: Animals; Anthelmintics; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anti-Ulcer Agents; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Forecasting; Horse Diseases; Horses; Siphonaptera; Tick Infestations; Veterinary Drugs

Historic data show that home flea infestations can be managed by treating all animals on the premises with a highly effective flea control product. The use of effective products has also been shown to reduce pruritus and minimize dermatologic lesions in both cats and dogs. Therefore, an in-home study was conducted in West Central Florida USA to evaluate the efficacy of a topically applied selamectin-sarolaner formulation to control fleas in naturally infested cats over a 12-week period. Thirty-seven cats in 21 households were treated once monthly with the selamectin-sarolaner topical solution. In the topical fluralaner treatment (positive control) group, forty-three cats in 20 households were treated once on day 0. A combined total of thirty dogs in both groups were treated once monthly with oral sarolaner. Fleas on cats were counted by flea combing, fleas on dogs were counted using visual area counts and fleas in the indoor premises were assessed using intermittent-light flea traps. Blinded-assessments of feline dermatologic lesions (modified-SCORFAD) were conducted monthly by a boarded-dermatologist and pruritus severity was evaluated by pet owners. Three consecutive monthly treatments of selamectin-sarolaner reduced flea populations on cats by 96.3 % within 7 days and by 100% from week 6 to the end of the 12-week study. The topical application of fluralaner reduced flea populations by 98.1 % within 7 days and efficacy reached 100% by week 12. At the end of the study, fleas were completely eradicated (from cats, dogs and homes) in every home regardless of treatment group. Owner reported cat pruritus was reduced by > 87 % in both treatment groups by week 12. Significant improvements in dermatologic lesion scores (> 81 %) were achieved by both products by the end of the study. Monthly applications of topical selamectin-sarolaner or topical fluralaner to cats living in the heavy flea challenge environment of West Central Florida USA were effective in eradicating flea infestations, reducing pruritus and improving dermatologic lesions.

Topics: Administration, Topical; Animals; Azetidines; Cat Diseases; Cats; Drug Combinations; Flea Infestations; Florida; Insecticides; Ivermectin; Spiro Compounds

An investigation was conducted in West Central Florida, USA to evaluate the efficacy of either topically applied fluralaner or topically applied selamectin to control flea infestations, minimize dermatologic lesions and reduce pruritus in naturally flea infested cats over a 12-week period. When dogs were present in the households, they were treated with either oral fluralaner (if household cats were treated with topical fluralaner) or oral sarolaner (if household cats were treated with topical selamectin).. Thirty-one cats in 20 homes were treated once with fluralaner topical solution on day 0 and 18 dogs in these homes were administered a single fluralaner chewable. Twenty-nine cats in 18 homes were treated once monthly with a selamectin topical solution for 3 treatments and 13 dogs in these same homes were treated once monthly for 3 treatments with a sarolaner chewable. Fleas on cats were counted by flea combing, fleas on dogs were estimated using visual area counts and fleas in the indoor premises were assessed using intermittent-light flea traps. Blinded-assessments of feline dermatologic lesions were conducted monthly and pruritus severity was evaluated by pet owners.. A single topical application of fluralaner reduced flea populations on cats by 96.6% within 7 days and by 100% at 12 weeks post-treatment. This efficacy was significantly greater than selamectin treatment where single topical application reduced flea populations on cats by 79.4% within 7 days of initial treatment and 3 consecutive monthly treatments reduced flea populations by 91.3% at the end of 12 weeks. At the end of the 12-week study, all fluralaner-treated cats were flea-free and this was significantly greater than the 38.5% of selamectin treated cats that were flea-free. At the end of the study, fleas were completely eradicated (from cats, dogs and homes) in 95.0% of fluralaner treatment group homes, significantly greater than the 31.3% of selamectin/sarolaner treatment group homes with complete flea eradication. Owner reported cat pruritus was reduced similarly in both treatment groups. Significant improvements in dermatologic lesion scores were achieved by day 30 in fluralaner treated cats and by day 60 in selamectin treated cats.. An in-home investigation in subtropical Florida found that 1 application of topical fluralaner eliminated flea infestations on cats and in homes significantly more effectively than 3 consecutive monthly doses of selamectin.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Flea Infestations; Florida; Isoxazoles; Ivermectin

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Europe; Female; Flea Infestations; Imidazoles; Isoxazoles; Ivermectin; Macrolides; Male; Neonicotinoids; Nitro Compounds; Pyrazoles; Tick Infestations; Treatment Outcome

To compare safety and efficacy of spinosad and selamectin and determine effects of those products on flea allergy dermatitis (FAD) in cats.. Randomized clinical trial. Animals-211 client-owned cats.. Cats with ≥ 5 fleas evaluated at 8 veterinary clinics were allocated to receive spinosad (50 to 100 mg/kg [22.7 to 45.5 mg/lb], PO; n = 139) or selamectin (≥ 6 mg/kg [≥ 2.7 mg/lb], topically; 72) once per month. Flea comb counts and FAD scores were determined on day -1, between days 27 and 33, and between days 85 and 95 (evaluations 1, 2, and 3, respectively); day 0 was the first day of drug administration.. The most common adverse event was vomiting (14.3% and 2.4% of spinosad- and selamectin-treated cats, respectively). Evaluation 2 and 3 geometric mean flea counts for spinosad-treated cats were significantly lower than those for selamectin-treated cats. Percentage reductions in flea counts for the spinosad and selamectin groups were 97.5% and 88.8% (evaluation 2) and 99.3% and 97.7% (evaluation 3), respectively. At evaluations 2 and 3, 70.6% and 92.6% of spinosad-treated cats and 29.4% and 64.7% of selamectin-treated cats were free of fleas, respectively. Weighted FAD scores for spinosad- and selamectin-treated cats decreased 94.2% and 80.0% during the study, respectively. Spinosad tablets were successfully administered during 98.1% of treatments.. Results of this study indicated spinosad and selamectin both reduced flea counts and FAD scores for cats, although spinosad was more effective. Monthly oral administration of spinosad may be practical for treatment of flea infestations and FAD in cats.

Topics: Animals; Cat Diseases; Cats; Drug Combinations; Ectoparasitic Infestations; Female; Insecticides; Ivermectin; Macrolides; Male; Siphonaptera; Tablets

In recent years Aelurostrongylus abstrusus has often been reported in Italy. This lungworm is very common in cat colonies due to its route of transmission. Deciding a therapeutic approach can be difficult in such colonies, because there is no certainty whether oral medicines administered with food, or with what dose, will be taken. In this field study, stool samples were taken from 42 cats and analysed for A. abstrusus L1 larvae with Baermann technique. Ten cats testing positive were treated with a spot-on formulation of selamectin 45 mg. Clinical examinations and laboratory tests, repeated four times in two months, demonstrated the success of the treatment in 9 of the 10 cats. Improvements in respiratory signs and general clinical condition were reported after treatment.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Italy; Ivermectin; Strongylida Infections

The efficacy of Oridermyl(®) (acaricidal/antibiotic/antifungal/anti-inflammatory ointment) and Revolution(®) (selamectin spot-on) was compared in a blinded randomized study on 24 adult cats with otoacariasis. Twelve cats were treated once daily for 10 d with Oridermyl(®) and 12 cats were treated on Day 0 with Revolution(®). Otitis was assessed with cytological counts of mean number of bacteria and yeast on Days 0 and 10, and scored clinically every other day. All auricular secretions were removed for mite count on Day 10. On Day 0, cytological examination confirmed the presence of secondary bacterial (24/24) and fungal (21/24) infections. No live mites were observed otoscopically after Day 4 and in auricular secretions at Day 10 in both groups. On Day 10, secondary infections were resolved for all cats treated with Oridermyl(®) but were present in all cats treated with Revolution(®). Improvement in clinical signs of otitis over time was superior in the Oridermyl(®) group (P < 0.001).

Topics: Acaricides; Animals; Bacterial Infections; Cat Diseases; Cats; Ear Canal; Female; Ivermectin; Male; Mite Infestations; Mites; Mycoses; Ointments; Otitis Externa; Treatment Outcome

Twenty adult, domestic short hair cats were randomly allocated into four groups of five cats and housed in separated cages. Each cat was infested with 25 fleas Ctenocephalides felis felis and 25 Ctenocephalides felis strongylus and 2 days later (day 0) the cats in group 1, 2 and 3 received a spot on application of selamectin, imidacloprid or fipronil, respectively, while the cats in group four were not treated. The cats were combed 48 h later, the fleas were removed, counted and their subspecies were determined. All the cats were reinfested with the same number of the two subspecies of fleas on days 7, 14, 21, 29 and 35. The efficacy of each treatment was calculated 48 h after each infestation. The mean number of fleas on the control cats was 16.4 C. f. felis and 13.4 C. f. strongylus. The three treatments were effective for the first 31 days for C. f. felis and for the full 37 days for C. f. strongylus. Over the first 31 days, the efficacy of selamectin ranged from 89 to 100% and 85 to 100% against C. f. felis and C. f. strongylus, respectively, the efficacy of imidacloprid ranged from 76 to 100% and 92 to 100% and the efficacy of fipronil ranged from 98 to 100% and 97 to 100% against C. f. felis and C. f. strongylus. There were no significant differences between the control of C. f. felis and C. f. strongylus by the three products.

Topics: Animals; Cat Diseases; Cats; Cross-Over Studies; Ectoparasitic Infestations; Female; Imidazoles; Insecticides; Ivermectin; Male; Neonicotinoids; Nitro Compounds; Pyrazoles; Siphonaptera; Time Factors; Treatment Outcome

A study was conducted to evaluate the efficacy of selamectin and fipronil-(S)-methoprene against adult cat fleas (Ctenocephalides felis), flea egg production, and the viability of flea eggs collected from treated cats. Cats were infested with approximately 50 adult fleas 2 days before treatment and weekly thereafter; flea eggs were collected and counted on days 0, 1, 2, and 3 and 48 and 72 hours after each weekly flea infestation. Live fleas were collected approximately 72 hours after treatment or infestation. Compared with fipronil-(S)-methoprene, selamectin provided significantly greater control of adult fleas from days 24 to 31 and significantly greater reduction in egg production from days 16 to 45. For the most part, both products significantly impacted larval and adult emergence for the entire 6-week study, with fipronil-(S)-methoprene providing significantly greater reduction in larval and adult emergence at week 6.

Topics: Administration, Cutaneous; Animals; Cat Diseases; Cats; Ectoparasitic Infestations; Insecticides; Ivermectin; Larva; Pyrazoles; Siphonaptera; Treatment Outcome

A topically applied formulation containing 10% imidacloprid+1% moxidectin (Advocate/Advantage multi) has been developed for monthly application to cats for the prevention of feline heartworm (HW) disease caused by Dirofilaria immitis; and for the treatment and control of flea infestations, ear mite infestations, and intestinal nematode infections. A study model was designed to evaluate the safety of this product in cats harboring adult D. immitis infections. Eighty adult cats (40 males/40 females) were each inoculated with 60 third-stage D. immitis larvae on test day (TD) 1. On TD 243-245 echocardiographic imaging was performed on each cat to confirm and estimate the number of adult D. immitis residing in the cardiovascular system. A total of 35 cats were subsequently eligible for safety evaluation based on inclusion criteria. Four treatment groups were established and randomly selected for treatment: imidacloprid+moxidectin solution at the label dose (n=9) (group 1), imidacloprid+moxidectin solution at 5x the Iabel dose (n=9) (group 2), 6% selamectin topical solution (Revolution) at the label dose (positive control, n=8) (group 3), and topical treatment with placebo (negative control, n=9) (group 4). All cats were treated on TD 250. Treatments for groups 1, 3, and 4 were repeated on TDs 278 and 306. Group 2 cats were euthanized and examined for adult D. immitis on TD 288. All other cats were euthanized and examined for adult D. immitis on TD 334. No adverse events attributable to treatment with the test articles were observed during the study. The geometric mean numbers of adult D. immitis recovered at necropsy from treatment groups 1-4 were 2.9, 3.2., 4.0, and 2.7, respectively. There were no statistically significant differences in the comparison of adult D. immitis recovered at necropsy (ANOVA overall group effect P-value of 0.5356). The results of this study demonstrate that imidacloprid+moxidectin topical solution can be used safely in cats heavily infected with adult D. immitis.

Topics: Animals; Anthelmintics; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Drug Therapy, Combination; Female; Imidazoles; Ivermectin; Macrolides; Male; Neonicotinoids; Nitro Compounds

The speed of kill of selamectin, imidacloprid, and fipronil-(S)-methoprene against Ctenocephalides felis infestations on cats for one month following a single treatment was evaluated. Eighty cats were randomly allocated so that there were 20 cats in four different treatment groups. On Days -2, 7, 14, 21, and 28, each cat was infested with 100 adult C. felis from the Kansas 1 flea strain. Following initial application only imidacloprid had caused a significant reduction in adult fleas on treated cats within 6 hours, but by 24 hours all three formulations had killed 96.7% of the fleas. At 7 days post treatment, all three formulations reduced flea populations within 6 and 24 hours by 68.4% and 99.4%, respectively. At 21 and 28 days after treatment, none of the formulations killed significant numbers of fleas as compared to controls within 6 hours of infestation. At 28 days after treatment, selamectin, fipronil-(S)-methoprene, and imidacloprid had killed 99.0%, 86.4%, and 72.6% of the fleas within 48 hours of infestation, respectively. This study demonstrates that the speed of kill of residual flea products on cats decreases throughout the month following application. It also demonstrated that selamectin provided the highest level of residual activity on cats against the Kansas 1 flea strain.

Topics: Administration, Cutaneous; Animals; Cat Diseases; Cats; Chemistry, Pharmaceutical; Ectoparasitic Infestations; Female; Imidazoles; Insecticides; Ivermectin; Male; Neonicotinoids; Nitro Compounds; Pyrazoles; Siphonaptera; Time Factors; Treatment Outcome

The efficacy of a novel avermectin, selamectin (Stronghold, Pfizer), was evaluated against naturally acquired aural infestations of Otodectes cynotis. Selamectin was administered topically in a single spot to the skin of each animal's back at the base of the neck in front of the scapulae at a minimum dosage of 6mgkg(-1). Thirty cats of a cattery of 120 animals with an endemic infestation were treated on days 0 and 30. Including untreated control cats was therefore not possible because of animal welfare consideration. Clinical examination and visualization of mites by otoscopic examination of the external ear canal and microscopic examination of aural debris/exudate were performed twice weekly from days 0 to 30. On day 0 (and day 28 if the ears canals were erythematous), a swab was taken from each canal and sent to bacteriology and mycology units for detection and identification of bacteria (Staphylococcus mainly) and yeast (Malassezia pachydermatis only). Selamectin was safe, parasites were killed before day 3 and eliminated before day 17. Selamectin was 100% effective against natural aural infestations, even if erythema (26-33% of cats) and scratch reflex (23-40% of cats) persisted for 2 weeks after the cats tested negative for mites.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Ear; Ear Diseases; Female; Ivermectin; Male; Mite Infestations; Mites

Speed of kill and percentage kill of nitenpyram (CAPSTAR) was compared to fipronil (Frontline) spot-on), imidacloprid (Bayvantage/Advantage), selamectin (Stronghold/Revolution) and cythioate (Cyflee) against adult fleas on cats and dogs 3 and 8h post-treatment. Selamectin was used on dogs only; cythioate was used on cats only. Groups of eight cats and eight dogs (four males and four females each) were experimentally infested with 100 unfed fleas 1 day prior to treatment with the test products. One group of cats and one group of dogs served as control. Fleas were collected from four cats and four dogs in each group (two males and two females) by combing 3h after treatment, the remaining four cats or dogs were combed 8h after treatment. In cats cythioate treatment resulted in a mean efficacy of 62.4 and 97.4% at 3 and 8h post-treatment, respectively. Imidacloprid efficacy at the same times was 26.9 and 82.8%, whereas fipronil efficacy was 24.3 and 62.6% efficacy, respectively. In dogs mean efficacy 3 and 8h after treatment with selamectin was 39.7 and 74.4%; with imidacloprid efficacy was 22.2 and 95.7%, respectively and 35.9 and 46.5%, respectively after treatment with fipronil. Nitenpyram was 100% effective in cats and 99.1% effective in dogs within 3h of treatment and 100% effective in cats and dogs within 8h.

Topics: Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Ectoparasitic Infestations; Female; Imidazoles; Insecticides; Ivermectin; Male; Neonicotinoids; Nitro Compounds; Pyrazoles; Pyridines; Siphonaptera; Time Factors

The efficacy of selamectin was evaluated against naturally acquired Trichodectes canis infestations on dogs and against Felicola subrostratus infestations on cats. Twenty dogs and 18 cats were randomly allocated to treatment with either a placebo or selamectin (6 mg/kg), administered topically once only on day 0. The treatment had no adverse effects in either the dogs or the cats. Efficacy was assessed by counting the live lice (adults and nymphs) on each animal by using a coat-parting technique on days -3, 7, 14, 21, 28, 35 and 42 for the dogs, and on days -1, 7, 21, 35 and 42 for the cats. On day 43, the number of live lice on each dog was also assessed by using a whole-body combing technique. Selamectin was 100 per cent effective in killing biting lice on the dogs and cats throughout the period of assessment; the louse counts on the treated dogs and cats were significantly lower than the pretreatment counts (P = 0.0001) and were also significantly lower than on the placebo-treated dogs (P < 0.05) and cats (P = 0.0001). There was a marked reduction in the prevalence of clinical signs associated with ectoparasite infestation in the treated dogs and no clinical signs were observed in any of the treated cats.

Topics: Administration, Cutaneous; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Insecticides; Ivermectin; Lice Infestations; Male; Phthiraptera; Treatment Outcome

To determine whether treatment with selamectin would reduce clinical signs of flea allergy dermatitis (FAD) in dogs and cats housed in flea-infested environments.. Randomized controlled trial.. 22 dogs and 17 cats confirmed to have FAD.. Animals were housed in carpeted pens capable of supporting the flea life cycle and infested with 100 fleas (Ctenocephalides felis) on days -13 and -2 and on alternate weeks with 10 to 20 fleas. On day 0, 11 dogs and 8 cats were treated with selamectin (6 mg/kg [2.7 mg/lb]). Dogs were retreated on day 30; cats were retreated on days 30 and 60. All animals were examined periodically for clinical signs of FAD. Flea counts were conducted at weekly intervals.. Throughout the study, geometric mean flea counts exceeded 100 for control animals and were < or = 11 for selamectin-treated animals. Selamectin-treated cats had significant improvements in the severity of miliary lesions and scaling or crusting on days 42 and 84, compared with conditions on day -8, and in severity of excoriation on day 42. In contrast, control cats did not have any significant improvements in any of the clinical signs of FAD. Selamectin-treated dogs had significant improvements in all clinical signs on days 28 and 61, but in control dogs, severity of clinical signs of FAD was not significantly different from baseline severity at any time.. Results suggest that topical administration of selamectin, even without the use of supplementary environmental control measures and with minimal therapeutic intervention, can reduce the severity of clinical signs of FAD in dogs and cats.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Dermatitis, Allergic Contact; Dog Diseases; Dogs; Ectoparasitic Infestations; Female; Ivermectin; Male; Siphonaptera; Treatment Outcome

The comparative efficacy of monthly administration of selamectin or lufenuron against Ctenocephalides felis felis on dogs and cats was evaluated over a 5-month period in flea-infested environments. Twenty-four dogs and 32 cats were randomly allocated to receiving a topical treatment with selamectin or an oral administration of tablets containing lufenuron/milbemycin oxime (for dogs) or lufenuron only (for cats). Each product was administered in accordance with the manufacturer's label recommendations. Eight dogs and four cats served as untreated sentinels. Treatments were administered on days 0, 30, 60, 90, and 120. Each animal received an application of 100 fleas on days -28 and -21, and then weekly applications of 20 fleas from days 91 through 147. Flea comb counts were performed on day -6, and every 2 weeks after day 0. From day 29 (dogs) or day 44 (cats) to day 150, geometric mean flea counts for selamectin were < or =0.4. Mean flea counts for animals assigned to treatment with selamectin were significantly lower (P=0.0001) than for animals assigned to treatment with lufenuron at all assessments after day 0.

Topics: Animals; Antiparasitic Agents; Benzamides; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Administration Schedule; Ectoparasitic Infestations; Female; Housing, Animal; Insecticides; Ivermectin; Male; Siphonaptera; Treatment Outcome

The topical endectocide selamectin (Revolution, Pfizer Animal Health) was evaluated in seven veterinary dermatology specialty clinics for its ability to control fleas on 75 dogs and 46 cats from single- and multiple-animal households. All animals were treated on days 0, 30, and 60 with a minimum unit dose of 6 mg/kg of selamectin(h) applied to the skin in a single spot at the base of the neck in front of the scapulae. The product was applied according to label instructions, and the use of other topical or environmental flea control products was prohibited during the study. Efficacy was assessed by percentage reductions in geometric mean flea comb counts. The reductions in flea numbers for dogs and cats combined were 90.6%, 97.0%, and 98.0% on days 30, 60, and 90, respectively, compared with day 0. This study demonstrates that selamectin, applied at 30-day intervals to dogs and cats, effectively controls flea infestations without other flea control products in single- and multiple-animal households.

Topics: Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Ectoparasitic Infestations; Female; Insecticides; Ivermectin; Male; Siphonaptera

Topics: Animals; Anthelmintics; Antiparasitic Agents; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Ectoparasitic Infestations; Female; Ivermectin; Male; Mice; Models, Chemical; Siphonaptera; Tick Infestations

Selamectin, 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22, 23-dihydro-5-(hydroxyimino)-avermectin B1 monosaccharide, is a novel endectocide with a unique combination of efficacy and safety in dogs and cats following both oral and topical administration. The compound is active against fleas and ticks, intestinal hookworms and ascarids, and immature heartworms. Also it is well tolerated at higher dosages than 22,23-dihydroavermectin B1a (DHAVM) or milbemycin oxime in Collies, which is a breed known to exhibit idiosyncratic sensitivity to avermectins.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Ectoparasitic Infestations; Female; Ivermectin; Male; Siphonaptera

Selamectin, a novel avermectin, was evaluated in two controlled studies (one in Beagles, one in domestic shorthaired cats) to determine an appropriate topical dose for efficacy against adult Ctenocephalides felis felis (C. felis) fleas on dogs and cats for 1 month. For each study, animals were allocated randomly to four treatments. One treatment consisted of the inert formulation ingredients (vehicle) administered as a negative control, and the other three treatments consisted of a single topical dosage of 3, 6, or 9mgkg(-1) of selamectin. In each study, selamectin was administered as a topical dose applied to the skin in a single spot at the base of the neck in front of the scapulae. Dogs and cats were infested with 100 viable unfed C. felis (50 males and 50 females) on days 4, 11, 18, and 27. Seventy-two hours (+/-2h) after each infestation, on days 7, 14, 21, and 30, a comb count to determine the number of viable fleas present on each animal was performed. Efficacy of selamectin on day 30 was used to select an appropriate dose. For dogs and cats, percentage reductions in geometric mean flea comb counts for the three selamectin treatments ranged from 94. 6 to 100% on days 7, 14, and 21, compared with the negative-control treatment. On day 30, reductions in flea comb counts were 81.5, 94.7, and 90.8% for dogs, and 79.8, 98.0, and 96.2% for cats treated with selamectin at 3, 6, or 9mgkg(-1), respectively. For day 30 flea comb counts for dogs and cats, analysis of variance showed that the three selamectin treatments resulted in significantly (P< or =0.05) lower counts than did the negative-control treatment. For dogs and cats, geometric mean flea counts for selamectin administered at a dosage of 3mgkg(-1) were significantly (P< or =0.05) higher than those for the 6 and 9mgkg(-1) treatment dosages combined. There were no significant differences in flea counts between the 6 and 9mgkg(-1) treatments. This analysis was confirmed by linear-plateau modeling. Thus, the optimal dose of selamectin for efficacy against adult fleas for both dogs and cats, as estimated by the turning point (plateau) in the dose response curve, was 6mgkg(-1).

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Administration Schedule; Ectoparasitic Infestations; Female; Ivermectin; Male; Siphonaptera

Selamectin was evaluated in eight controlled studies (4 in dogs, 4 in cats) to determine the efficacy of a single topical unit dose providing the recommended minimum dosage of 6mgkg(-1) against Ctenocephalides felis felis and Ctenocephalides canis fleas on dogs and against C. felis on cats. In addition, the effect of bathing on the efficacy of selamectin against C. felis was evaluated. Identical studies were performed in Beagles and domestic shorthaired cats. For each study, animals were allocated randomly to treatments of 8-12 animals each. All studies (dog studies A, B, C, and D and cat studies A, B, C, and D) evaluated the efficacy of selamectin without bathing. In addition, study C in both dogs and cats evaluated efficacy with a shampoo bath at 24h after dosing, and study D evaluated the efficacy of selamectin with water soaking at 2h after dosing or with a shampoo bath at 2-6h after dosing. Dog study B evaluated efficacy against C. canis, whereas all other studies used C. felis. In each study, selamectin was administered on day 0 as a topical dose that was applied directly to the skin in a single spot at the base of the neck in front of the scapulae. Dogs and cats were infested with approximately 100 viable unfed C. felis or C. canis on days 4, 11, 18, and 27. On days 7, 14, 21, and 30, approximately 72h after infestation, a comb count of the number of viable fleas present on each animal was made. For C. felis and C. canis for dogs and cats, compared with controls, selamectin achieved significant reductions in geometric mean adult flea comb counts of > or =98.9% on days 7, 14, and 21 in all eight studies. On day 30, the reduction for C. felis remained at or above 98.0%. This included the dogs and cats that were soaked with water or bathed with shampoo at 2, 6, or 24h after treatment. There were no significant (P>0.05) differences between the flea counts from selamectin-treated animals in these studies, regardless of bathing status. On day 30, a significant reduction of 91.8% was achieved against C. canis on dogs. Thus, these studies demonstrated that a single topical unit dose of selamectin was highly effective against adult fleas on dogs and cats for at least 27 days.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Administration Schedule; Ectoparasitic Infestations; Female; Ivermectin; Male; Siphonaptera; Time Factors

The adulticidal, ovicidal, and larvicidal effects of selamectin against flea (Ctenocephalides felis felis) infestations on dogs and cats were evaluated in a series of seven controlled and masked studies (three in cats, four in dogs). Animals were randomly allocated to treatment with either selamectin at a minimum dosage of 6mgkg(-1) in the commercial formulation or one of two negative-controls (0.9% NaCl solution or the vehicle from the commercial formulation). Treatments were administered topically in a single spot on the skin at the base of the neck in front of the scapulae. Speed of kill, measured by flea comb counts at 12h intervals during the 48h immediately following a single treatment on day 0, was evaluated in two studies. One study was in dogs and the other in cats, and each animal was infested with approximately 100 unfed viable adult fleas prior to treatment. Reductions in geometric mean flea counts for selamectin compared with saline were >98% between 24 and 36h after treatment in dogs, and between 12 and 24h after treatment in cats (P< or =0.0006). Efficacy in reducing flea egg hatch and larval development was evaluated in four studies, in which dogs and cats were treated once on day 0 and then repeatedly infested with approximately 600 fleas. Flea eggs were collected approximately for 72h after each infestation, on days 3, 7, 14, 21, and 30, counted, and cultured to determine their hatchability and subsequent larval development. Compared with the vehicle, selamectin was highly effective in reducing flea egg hatch (>92% in cats) and larval development (> or =95% for dogs and cats), and emergence of adults (97.8-100% for dogs, 85.6-100% for cats) for 30 days. Effects of exposure to hair coat debris were investigated in a study with dogs treated once on day 0 and repeatedly infested with 100 adult fleas. Debris (dander, flea faeces, hair, scales) was collected on days 1, 7, 14, 21, and 30 and added to normal flea eggs or larvae for incubation. Compared with debris from vehicle-treated dogs, debris from selamectin-treated dogs was highly effective in preventing egg hatch (>96%), in killing larvae (>98%) and in preventing larval development to adults (>99%) (P

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Administration Schedule; Ectoparasitic Infestations; Female; Housing, Animal; Ivermectin; Life Cycle Stages; Male; Siphonaptera

The efficacy of selamectin, a novel avermectin, in protecting dogs and cats against experimentally induced environmental flea (Ctenocephalides felis felis) infestations, was evaluated in a series of controlled and masked studies. Purpose-bred shorthaired cats and Beagles were randomly allocated to treatment with either selamectin at a minimum dosage of 6mgkg(-1) of body weight in the commercial formulation or the negative control treatment (vehicle only), and housed in controlled simulated home environments capable of supporting the flea life cycle. Day 0 was defined as the first day of treatment. Treatments were administered topically in a single spot on the skin at the base of the neck in front of the scapulae. In environmental challenge studies, which were designed to evaluate the efficacy of selamectin in the treatment and control of established flea infestations, dogs and cats were each infested with 100 fleas on days -28 and -21 and placed in carpeted rooms in order to establish high levels of active flea infestation prior to day 0. Treatments were administered monthly for 3 months. Flea comb counts were performed on days 14, 29, 44, 59, 74, and 90. Reductions in geometric mean flea comb counts for selamectin, compared with vehicle, were >99% from day 14 onwards for dogs, and >92% on day 29 and >99% on days 44, 59, 74, and 90 for cats (P=0.0001). In prevention of environmental infestation studies, dogs and cats were placed in environments capable of supporting flea infestations and given monthly treatments for 2 months, commencing on day 0. Animals were infested with 100 fleas on days 1 and 7, and flea comb counts were performed on days 29, 44, and 60. Reductions in geometric mean flea comb counts for selamectin, compared with vehicle, were >99% on days 29, 44, and 60 (P=0.0001) for dogs and cats. Monthly administration of selamectin to dogs and cats housed in environments highly suited to completion of the flea life cycle was shown to be highly effective in the treatment and prevention of flea infestations, without the need for supplementary environmental control measures.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Administration Schedule; Ectoparasitic Infestations; Female; Housing, Animal; Ivermectin; Male; Siphonaptera

Two controlled and masked multi-centre studies were conducted to examine the efficacy of a novel topical avermectin, selamectin, against natural flea infestations on 418 dogs and 345 cats. Veterinary patients with viable flea infestations were enrolled in the studies, which were conducted in United Kingdom, France, Germany, and Italy. Animals were allocated randomly in a 2:1 ratio to one of two treatments: either selamectin alone at a minimum dosage of 6mgkg(-1) or fenthion at recommended dose rates. Concurrent use of an environmental spray (containing methoprene and either pyrethrins or permethrin) was permitted only for fenthion-treated animals. In-contact cats and dogs (animals living in the same home) received the same treatment as the first animal enrolled from the household, if recommended by the veterinarian. Study day 0 was defined as the day of first treatment. Animals were treated on days 0, 30, and 60, and flea comb counts and clinical evaluations were conducted on days 0, 14, 30, 60, and 90. Analysis of variance of ln(flea count+1) showed that values were significantly lower for selamectin alone compared with fenthion (with or without the concurrent use of an environmental spray) in dogs on days 30, 60, and 90 (P<0.05) and in cats on days 14, 30, 60, and 90 (P<0.01). For selamectin, the reductions in geometric mean flea counts on days 14, 30, 60, and 90, compared with day 0, were 92.5, 90.7, 98.1, and 99.1%, respectively, for dogs and 92.8, 92.7, 97.7, and 98.4%, respectively, for cats. Selamectin was shown to be safe and highly effective in the control of naturally acquired flea infestations on dogs and cats presented as veterinary patients in Europe.

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Administration Schedule; Ectoparasitic Infestations; Europe; Female; Housing, Animal; Ivermectin; Male; Siphonaptera

A series of randomized, controlled, masked field studies was conducted to assess the efficacy and safety of selamectin in the treatment of flea infestations on dogs and cats, and in the prevention of heartworm infection in dogs. In addition, observations were made on the beneficial effect of selamectin treatment on dogs and cats showing signs of flea allergy dermatitis (FAD). In all studies selamectin was applied topically, once per month, in unit doses providing a minimum dosage of 6mgkg(-1). Dogs and cats with naturally occurring flea infestations, some of which also had signs associated with FAD, were assigned randomly to receive three months of topical treatment with selamectin (220 dogs, 189 cats) or a positive-control product (dogs: fenthion, n=81; cats: pyrethrins, n=66). Selamectin was administered on days 0, 30, and 60. Day 0 was defined as the day that the animal first received treatment. Flea burdens were assessed by flea comb counts and clinical evaluations of FAD were performed before treatment, and on days 14, 30, 60, and 90. On days 30, 60, and 90, mean flea counts in selamectin-treated dogs were reduced by 92.1, 99.0, and 99.8%, and mean flea counts in fenthion-treated dogs were reduced by 81.5, 86.8, and 86.1%, respectively, compared with day 0 counts. Also, on days 30, 60, and 90, mean flea counts in selamectin-treated cats were reduced by 92.5, 98.3, and 99.3%, and mean flea counts in pyrethrin-treated cats were reduced by 66.4, 73.9, and 81.3%, respectively, compared with day 0 counts. Selamectin also was beneficial in alleviating signs in dogs and cats diagnosed clinically with FAD. A total of 397 dogs free of adult heartworm infection from four heartworm-endemic areas of the USA were allocated randomly to six months of treatment with selamectin (n=298) or ivermectin (n=99). Selamectin achieved a heartworm prevention rate of 100%, with all dogs testing negative for microfilariae and adult heartworm antigen on days 180 and 300. Selamectin was administered to a total of 673 dogs and 347 cats having an age range of 6 weeks to 19 years (3954 doses). The animals included 19 purebred or crossbred Collies (Bearded, Border, and unspecified). There were no serious adverse events. Results of these studies indicated that selamectin was highly effective in the control of flea infestations in dogs and cats without the need for simultaneous treatment of the environment or of in-contact animals and also was beneficial in alleviating signs associated

Topics: Animals; Anthelmintics; Antiparasitic Agents; Cat Diseases; Cats; Dirofilariasis; Dog Diseases; Dogs; Drug Administration Schedule; Ectoparasitic Infestations; Female; Ivermectin; Male; North America; Siphonaptera

In a series of six controlled studies (four in dogs, two in cats), heartworm-free dogs and cats were inoculated with Dirofilaria immitis larvae (L(3)) prior to topical treatment with the novel avermectin selamectin or a negative control containing inert formulation ingredients (vehicle). Selamectin and negative-control treatments were administered topically to the skin at the base of the neck in front of the scapulae. In dogs, selamectin was applied topically at dosages of 3 or 6mgkg(-1) at 30 days post-inoculation (PI), or of 3 or 6mgkg(-1) at 45 days PI, or of 6mgkg(-1) at 60 days PI. Cats were treated topically with unit doses providing a minimum dosage of 6mgkg(-1) selamectin at 30 days PI. Of the animals that were treated 30 days PI, some dogs were bathed with water or shampoo between 2 and 96h after treatment, and some cats were bathed with shampoo at 24h after treatment. Between 140 and 199 days PI, the animals were euthanized and examined for adult D. immitis. Adult heartworms developed in all control dogs (geometric mean count, 18.7 worms) and in 88% of control cats (geometric mean count, 2.1 worms). Selamectin was 100% effective in preventing heartworm development in dogs when administered as a single topical dose of 3 or 6mgkg(-1) at 30 days after infection, 3 or 6mgkg(-1) at 45 days after infection, or 6mgkg(-1) at 60 days after infection. Selamectin was 100% effective against heartworm infections in cats when administered as a single topical unit dose of 6mgkg(-1). Bathing with water or shampoo between 2 and 96h after treatment did not reduce the efficacy of selamectin as a heartworm prophylactic in dogs. Likewise, bathing with shampoo at 24h after treatment did not reduce the efficacy of selamectin in cats. These studies demonstrated that, at the recommended dosage and treatment interval, a single topical administration of selamectin was 100% effective in preventing the development of D. immitis in dogs and cats.

Topics: Administration, Topical; Animals; Anthelmintics; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Dog Diseases; Dogs; Drug Administration Schedule; Italy; Ivermectin; United States

The efficacy of a novel avermectin, selamectin, was evaluated against naturally acquired aural infestations of Otodectes cynotis on dogs and cats. In four controlled and masked studies conducted in the USA and Europe, animals were allocated randomly to treatment with either selamectin at a minimum dosage of 6mgkg(-1) (range, 6-12. 5mgkg(-1)) or the vehicle only from the commercial formulation of selamectin (negative control). Treatments were administered topically in a single spot to the skin of each animal's back at the base of the neck in front of the scapulae. Cats were treated on day 0 only, and dogs were treated either on day 0 only or on days 0 and 30. The ears of dogs were examined otoscopically on day 14 for the presence of viable mites. Mite counts were conducted on day 30 for animals that had received one dose and on day 60 for animals that had received two doses. Percentage reductions in geometric mean mite counts for selamectin treatment compared with the vehicle were 100% for all animals on all count days. Analysis of variance, confirmed by Savage Scores, showed that ln(mite count+1) values were significantly (P< or =0.0015) lower for selamectin than for the vehicle for all animals on all count days. Thus, selamectin administered topically at a minimum dosage of 6mgkg(-1) was safe and 100% effective against naturally acquired aural infestations of O. cynotis in dogs and cats after a single dose or after two doses administered 1 month apart.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Italy; Ivermectin; Male; Mite Infestations; United States

A series of randomized, controlled and masked field studies was conducted in veterinary patients to evaluate the efficacy of selamectin, a novel avermectin, in the treatment of naturally occurring Sarcoptes scabiei infestations on dogs and Otodectes cynotis infestations on dogs and cats. A total of 342 dogs and 237 cats participated in these studies, which were conducted at 40 veterinary practices in the USA and Europe. Animals were randomly assigned to treatment with selamectin or a positive-control product (existing approved products). Selamectin was administered as a unit dose providing a minimum of 6mgkg(-1) (range: 6-12mgkg(-1)) in a topical preparation applied to the skin in a single spot on day 0 (O. cynotis in cats, n=144), or on days 0 and 30 (O. cynotis and S. scabiei in dogs, n=83 and n=122, respectively). The presence of parasites was assessed before treatment and at 30 days (for all studies) and 60 days (for O. cynotis and S. scabiei dog studies) after first treatment. The animals were also evaluated clinically at each assessment period. Based on skin scrapings, the efficacy of selamectin against S. scabiei infestations on dogs was >95% by day 30, and 100% by day 60. Against O. cynotis, selamectin eliminated mites in 94-100% of cats by day 30, and in 90% of dogs by day 60. The positive-control products achieved similar results. Thus, selamectin was safe and effective against ear mites in dogs and cats and sarcoptic mange in dogs when used in field (veterinary patient) studies in dogs and cats of a wide variety of ages and breeds.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Italy; Ivermectin; Male; Mite Infestations; Sarcoptes scabiei; United States

The efficacy of selamectin against experimentally induced and naturally acquired infections of adult ascarids (Toxocara cati) and adult hookworms (Ancylostoma tubaeforme) was evaluated in five controlled studies in cats. Two studies evaluated the efficacy of selamectin against both ascarid (natural or induced) and hookworm (induced) infections; two studies evaluated the efficacy of selamectin against single natural infections of T. cati or A. tubaeforme; and the fifth study evaluated the efficacy of selamectin against induced infections of A. tubaeforme. Cats received selamectin topically in unit doses designed to deliver a minimum of 6mgkg(-1). Treatments were applied to the skin on each animal's back at the base of the neck in front of the scapulae. For experimentally induced infections, cats were inoculated orally with approximately 500 embryonated eggs of T. cati 56 days prior to treatment and/or approximately 150-250 larvae (L(3)) of A. tubaeforme 30 or 42 days prior to treatment. For both induced and naturally acquired infections, cats were allocated randomly to treatments (6-12 cats per treatment) on the basis of fecal egg counts to receive either selamectin or a vehicle containing the inert formulation ingredients. In all studies, adult worm counts were performed at necropsy 14 days after the last treatment administration. Against T. cati, a single application of selamectin provided a 100% reduction in the geometric mean number of adult worms for both experimentally induced and naturally acquired infections. Against A. tubaeforme, a single administration of selamectin provided a 99.4% reduction in the geometric mean number of adult worms in cats with natural infections, and an 84.7-99.7% reduction in adult worms in cats with induced infections. Two doses of selamectin administered at monthly intervals provided a 91.9% reduction in the geometric mean number of adult A. tubaeforme worms in cats with experimentally induced infections. The geometric mean numbers of adult worms (T. cati and A. tubaeforme) from selamectin-treated cats were significantly (P< or =0.0018) lower than for vehicle-treated cats in all studies. Thus, a single topical unit dosage providing a minimum dosage of 6mgkg(-1) selamectin was highly effective in the treatment of naturally acquired and experimentally induced infections of T. cati and A. tubaeforme in cats.

Topics: Administration, Topical; Ancylostoma; Ancylostomiasis; Animals; Anthelmintics; Cat Diseases; Cats; Female; Italy; Ivermectin; Male; Toxocara; Toxocariasis; United States

A series of randomized, controlled, masked, field (veterinary patient) studies were conducted in the USA and Europe to evaluate the efficacy of selamectin, a novel macrocyclic lactone of the avermectin subclass, in the treatment of naturally acquired gastrointestinal nematode infections in cats. After confirmation of ascarid and/or hookworm infection, 298 cats of various ages and breeds were randomly assigned to treatment with selamectin (n=202) or an existing commercially approved positive-control product (n=96). Unit doses of selamectin (providing a minimum dosage of 6mgkg(-1)) were administered topically to the skin in a single spot at monthly intervals. Quantitative fecal examinations were performed on days 0 (before treatment), 30, and 60. In the selamectin-treated cats, fecal ascarid egg counts were reduced by 99.6 to 100% on day 30, and by 99.9 to 100% on day 60. Fecal hookworm egg counts were reduced by 98.3% on day 30, and by 100% on day 60 in the selamectin-treated cats. The positive-control products achieved reductions in egg counts of 96.5 to 100% (ascarids) and 98.9 to 99.9% (hookworms). These studies have shown that monthly topical administration of selamectin is safe and highly effective in the treatment of naturally acquired ascarid and hookworm infections in cats.

Topics: Ancylostomatoidea; Animals; Anthelmintics; Cat Diseases; Cats; Ivermectin; Mebendazole; Nematode Infections; Parasite Egg Count; Praziquantel; Pyrantel

To evaluate efficacy of monthly administration of selamectin and fipronil against Ctenocephalides felis in cats.. Randomized controlled trial.. 36 healthy cats.. Cats known to be free of fleas were infested with 100 unfed adult fleas on days -28 and -21. On days 0, 30, 60, 90, and 120, sixteen cats (8 pairs/treatment group) were treated by topical administration of selamectin (6 mg/kg [2.7 mg/lb] of body weight) or fipronil (7.5 mg/kg [3.4 mg/lb]). Four control cats (2 pairs) were not treated. On day -6 and every 2 weeks after initial treatment, comb counts were performed to detect fleas. Flea counts were recorded, and fleas (< or =50) that had been removed were replaced onto the cat. On day 89, fleas were not replaced. On day 91 and every 7 days until the end of the study (day 150), cats were challenged with 20 adult fleas. Flea counts were compared between and within treatments.. 14 days after treatment, geometric mean flea counts were reduced by 71.2% by fipronil treatment and 35.3% by selamectin treatment. Both treatments resulted in 97 to 98% reduction in flea counts on day 29 and 99.8 to 100% reduction from day 44 to the end of the study.. Selamectin is as effective as fipronil in treating infestation in cats housed for 3 months in a flea-infested environment under conditions known to support the flea life cycle and in protecting against subsequent weekly challenges with C felis for an additional 2 months.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Ectoparasitic Infestations; Female; Ivermectin; Least-Squares Analysis; Male; Pyrazoles; Siphonaptera

The safety and efficacy of a new spot-on formulation of selamectin plus sarolaner were evaluated for the treatment and control of natural flea infestations on cats in two non-randomised, multi-centre clinical trials conducted in 8 different locations in Queensland, Australia.. One hundred and four cats from 65 different households were enrolled across the two studies. Demographic characteristics of cats in the two studies were similar. The new spot-on formulation of selamectin and sarolaner was administered topically once a month for 3 consecutive months at a minimum dosage of 6 mg/kg selamectin (dose range 6-12 mg/kg) plus 1 mg/kg sarolaner (dose range 1-2 mg/kg). Cats were dosed on Days 0 (pre-treatment), 30 and 60 and physical examinations and flea counts were conducted on Days 0, 30, 60 and 90. Efficacy assessments were based on the percentage reduction in live flea counts post-treatment compared to Day 0.. In Study A, at enrolment, primary cats had flea counts ranging from 6 to 107 (arithmetic mean 21.0). The selamectin and sarolaner spot-on formulation resulted in arithmetic mean efficacy of 98.0%, 100% and 100% on Days 30, 60 and 90, respectively. In Study B, at enrolment, primary cats had flea counts ranging from 6 to 22 (arithmetic mean 10.0). The selamectin and sarolaner spot-on formulation resulted in arithmetic mean efficacy of 99.7%, 100% and 100% on Days 30, 60 and 90, respectively.. The new spot-on formulation of selamectin plus sarolaner topically administered at monthly intervals at the minimum dosage of 6.0 mg/kg selamectin and 1.0 mg/kg sarolaner was safe and highly effective against natural infestations of fleas under a range of geographical conditions, representative of both tropical and subtropical regions of Australia.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Australia; Azetidines; Cat Diseases; Cats; Flea Infestations; Insecticides; Ivermectin; Siphonaptera; Spiro Compounds; Treatment Outcome

Topics: Administration, Topical; Animals; Antinematodal Agents; Azetidines; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Female; Ivermectin; Male; Spiro Compounds

Ancylostoma ceylanicum, a species of hookworm, is a common parasite of dogs and cats in the Asia-Pacific region. The objective of this study was to determine the efficacy of a single topical treatment of selamectin (Revolution®) against A. ceylanicum in experimentally infected cats. 12 kittens were injected with 300 infective stage larvae (L3) of A. ceylanicum by the subcutaneous route. Faecal samples were examined daily (days 7-15) for the presence of hookworm eggs. On day 18 kittens were stratified by faecal egg count and randomly allocated in equal numbers to control (n = 6) and treatment (n = 6) groups. Faecal egg counts were then performed daily (days 14-27) or every 3 days (days 28-51) until the end of the study and compared between the treated and control groups. Kittens in the treatment group were administered a single topical dose of selamectin (Revolution®), per label recommendations (6 mg/kg), on day 19. Kittens in the control group were not treated. At 4 days post-treatment, no hookworm eggs were detected in the treated group. Faecal samples from this group remained negative throughout the study, the treatment efficacy was 100% egg reduction (P < .0001). Average faecal egg counts remained high (558 ± 231 eggs per gram) in the untreated control group until the end of the study period. In conclusion, a single topical treatment of selamectin (Revolution®) at the recommended dose was highly efficacious against infection with A. ceylanicum in cats.

Topics: Administration, Topical; Ancylostoma; Ancylostomiasis; Animals; Antinematodal Agents; Cat Diseases; Cats; Ivermectin

The efficacy and safety of a new topical formulation containing selamectin plus sarolaner (Revolution® Plus / Stronghold® Plus, Zoetis) was evaluated for the prevention of heartworm (Dirofilaria immitis) disease and the treatment of roundworm infection in cats enrolled as veterinary patients in two field studies conducted in Japan. In the heartworm field study, 91 cats negative for D. immitis antigen and anti-D. immitis antibody were enrolled and received 9 monthly topical treatments with selamectin plus sarolaner during the period of April to December 2015. Efficacy was assessed by testing post-treatment blood samples collected 8, 12, and 15 months after initiation of treatment for the presence of D. immitis antigen and anti-D. immitis antibody. Eighty-seven cats completed the entire study and were included in the determination of efficacy. No D. immitis antigen or anti-D. immitis antibody were detected in any of the post-treatment samples. In the roundworm field study, completed in the period from April to November 2015, 64 cats with ≥100 roundworm eggs per gram (EPG) of feces were enrolled and allocated randomly in a 1:1 ratio, to receive either selamectin plus sarolaner or emodepside plus praziquantel (Profender®, Bayer). Treatments were administered topically on Days 0 and 30, and efficacy was assessed by fecal EPG counts conducted on Days 14, 30, and 60. All cats completed the entire study. At enrollment, all cats were infected with Toxocara cati. Compared to pre-treatment, geometric mean T. cati EPG counts on Days 14, 30, and 60 were reduced by >99.9% in both treatment groups. There were no treatment-related adverse events in either study. Monthly topical administration of Revolution® Plus / Stronghold® Plus providing a minimum of 6 mg/kg selamectin and 1 mg/kg sarolaner was safe and effective in the prevention of heartworm disease and the treatment of roundworm infection in cats enrolled as veterinary patients in Japan.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Azetidines; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Drug Compounding; Female; Helminthiasis; Intestinal Diseases, Parasitic; Ivermectin; Male; Nematode Infections; Parasite Egg Count; Random Allocation; Spiro Compounds; Toxocara; Treatment Outcome

Topics: Administration, Topical; Animals; Antiparasitic Agents; Azetidines; Cat Diseases; Cats; Drug Therapy, Combination; Ectoparasitic Infestations; Ivermectin; Japan; North America; Parasitic Diseases, Animal; Spiro Compounds

Objectives The bronchial lumen to pulmonary artery (BA) ratio is utilized to evaluate pulmonary pathology on CT images. The BA ratio may be unreliable when changes are present in bronchial and pulmonary arteries concurrently. Bronchial lumen to vertebral body (BV) and pulmonary artery to vertebral body (AV) ratios have been established in normal cats and may serve as an alternative. This study aimed to evaluate the BV, AV and BA ratios in cats before and after infection with Dirofilaria immitis, with and without selamectin administration, and to characterize the distribution of disease. Methods Archived CT images were reviewed from three groups of cats: D immitis-infected untreated (n = 6); infected pretreated with selamectin (n = 6); and uninfected untreated (n = 5). The BV, AV and BA ratios were calculated for all lung lobes for baseline (D0) and day 240 (D240) postinfection. Ratios and percentage change from baseline were compared between lobes and between groups. Results BV and AV ratios were more consistent in identifying abnormalities when disease was present in bronchial and arteries concurrently than BA ratios. Infected untreated cats had significant changes in both BV and AV ratios and percentage change from baseline. Abnormal BV and AV ratios were noted in the infected selamectin group, although less widely distributed. Conclusions and relevance The BV and AV ratios more accurately identified bronchial and pulmonary artery abnormalities in D immitis-infected cats. Both bronchial and pulmonary artery changes were present in infected cats, decreasing the diagnostic application of the BA ratio. Pulmonary artery changes were more widely distributed than bronchial changes in the lung. Heartworm-infected cats receiving selamectin had bronchial and pulmonary artery changes but to a lesser extent than untreated heartworm-infected cats. The CT-derived BV and AV ratios are a useful measure to evaluate lung disease of cats.

Topics: Animals; Bronchi; Case-Control Studies; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Female; Filaricides; Ivermectin; Male; Pulmonary Artery; Thoracic Vertebrae; Tomography, X-Ray Computed

Topics: Animals; Antiparasitic Agents; Azetidines; Cat Diseases; Cats; Ectoparasitic Infestations; Europe; Ivermectin; Parasitic Diseases, Animal; Spiro Compounds

The efficacy of a new spot-on formulation of selamectin plus sarolaner against induced flea infestations in cats was confirmed in three placebo-controlled, blinded studies. Purpose-bred adult cats (n=8/group) were blocked by pre-treatment flea counts and randomly allocated to treatment with either a placebo or with the spot-on formulation at the minimum dose of 6.0mg selamectin and 1.0mg sarolaner per kg bodyweight. Treatments were applied topically once on Day 0. All cats were infested with approximately 100 unfed, adult Ctenocephalides felis prior to treatment and at weekly intervals for 5 weeks. In Studies 1 and 2 comb counts were conducted to determine the numbers of viable fleas 24h after treatment and subsequent weekly infestations. In Study 3, flea counts were conducted at 6, 12, 24 and 48h after treatment and 3, 6, 12 and 24h after subsequent weekly infestations to evaluate the speed of kill against fleas. Cats in the placebo-treated groups maintained flea infestations throughout all studies. In Study 1, no live fleas were found on any of the treated cats, resulting in 100% efficacy for 5 weeks after a single treatment (P≤0.0001). In Study 2, selamectin/sarolaner reduced flea counts by 92.4% immediately after treatment and by 97.7%-100% after re-infestations for five weeks (P≤0.0001). In the speed of kill study, selamectin/sarolaner started killing fleas within 12h after treatment administration and within 6h following re-infestation for at least 28days. Efficacy was 98.1% by 24h after treatment and 100% within 24h after re-infestations for 5 weeks. A single topical administration of a new spot-on formulation of selamectin plus sarolaner at the minimum dose rapidly and consistently kills fleas on cats for at least 5 weeks.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Female; Flea Infestations; Isoxazoles; Ivermectin; Male; Random Allocation; Time Factors; Treatment Outcome

The efficacy of a new spot-on formulation of selamectin/sarolaner was evaluated against induced Otodectes cynotis infestations in cats in two randomized, blinded studies. Fourteen and 16 cats were randomly assigned to treatment groups in Studies 1 and 2, respectively. On Day 0, animals were either treated with placebo or with the spot-on formulation at the minimal dose of 6.0mg selamectin and 1.0mg sarolaner per kg bodyweight. Treatments were administered topically at the base of the neck. Presence of live mites was evaluated 14days after treatment administration by otoscopic examination and total live mite counts (adults plus immature) were conducted on Day 30 by ear lavage. Efficacy was calculated based on the reduction of mean total live mite counts on Day 30 in the selamectin/sarolaner-treated group versus the placebo-treated group. There were no treatment-related adverse reactions during the studies, apart from one cat in each treatment group with alopecia at the administration site. In both studies combined, live mites were present on Day 14, in 14 out of 15 cats in the placebo-treated groups and in 2 out of 15 cats in the selamectin/sarolaner-treated groups. On Day 30, the arithmetic mean live mite counts were 576.9 and 875.8 in the placebo-treated groups and 5.8 and 4.7 in the selamectin/sarolaner-treated groups, in Studies 1 and 2, respectively. The live mite counts were significantly (P≤0.0021) lower in the selamectin/sarolaner-treated groups compared to the placebo-treated groups with efficacies of 99.2% and 99.3%, in Studies 1 and 2 respectively. A single administration of a new spot-on formulation of selamectin/sarolaner at the minimum dose was safe and highly efficacious in the treatment of ear mite infestations in cats.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Female; Isoxazoles; Ivermectin; Male; Mite Infestations; Parasite Load; Psoroptidae; Random Allocation; Time Factors; Treatment Outcome

A new spot-on formulation of selamectin plus sarolaner was evaluated against fleas for adulticidal efficacy, and for the effect on egg production and hatching when applied to flea-infested cats. Ten male and ten female adult domestic shorthair cats were randomly assigned to one of two treatment groups based on pre-treatment flea counts. Cats received topical treatment on Day 0 in a single spot to the dorsal scapular area with either a placebo formulation or with the combination formulation at the minimal dose of 6.0mg selamectin plus 1.0mg sarolaner per kg bodyweight. On Days -1, 5, 12, 19, 26 and 33, cats were infested with approximately 100 (±5) unfed Ctenocephalides felis fleas. At 24h after treatment or 48h after subsequent flea infestation, cats were housed for a 20-h period in a cage to allow collection of flea eggs. At the end of this period, flea eggs were collected from the cages and cats were combed to remove and count live fleas. Emerged viable larvae and emerged adult fleas were counted 3days and 35days, respectively, after egg collection. The new spot-on formulation of selamectin plus sarolaner provided 100% efficacy against adult fleas up to Day 36 following a single application. Fleas on placebo-treated cats produced large numbers of eggs throughout the study, with individual counts ranging from 110 to 1256 eggs. Following treatment, four flea eggs were collected from a single selamectin/sarolaner-treated cat on Day 29, but there were no eggs collected from any other selamectin/sarolaner-treated animal during the study. No larvae or adult fleas developed from these four eggs. From the eggs collected from the placebo-treated cats, the mean percentage of live larvae and adults that emerged ranged from 67.3% to 84.2% and from 50.7% to 81.8%, respectively. A single topical treatment with a new spot-on formulation of selamectin plus sarolaner at the minimum label dose thus controlled fleas on cats and was 100% effective in preventing flea reproduction for over one month after treatment.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Ctenocephalides; Female; Flea Infestations; Isoxazoles; Ivermectin; Male; Random Allocation; Reproduction; Treatment Outcome; Zygote

Topics: Acaricides; Administration, Topical; Animals; Cat Diseases; Cats; Europe; Female; Isoxazoles; Ivermectin; Male; Random Allocation; Tick Control; Tick Infestations; Ticks; Time Factors; Treatment Outcome

The efficacy of a new spot-on formulation of selamectin plus sarolaner for cats was evaluated against induced infections with Ancylostoma tubaeforme (hookworm) and Toxocara cati (roundworm). Five laboratory studies were conducted using adult, purpose-bred cats. Four of the studies were designed to evaluate efficacy of the combination against A. tubaeforme, the dose-limiting gastrointestinal nematode species for selamectin. In two of these studies non-interference between selamectin and sarolaner was also evaluated. The fifth study evaluated efficacy of the combination against mixed infections of A. tubaeforme and T. cati. The hookworm isolates in three studies were of US origin, as was the roundworm isolate. In the two remaining studies, cats were inoculated with a hookworm isolate of European origin. Cats were inoculated with 150 (±50) to 200 (±50) infective hookworm larvae 30-42days prior to treatment and with 400 infective roundworm eggs 60days prior to treatment. Cats were ranked by pre-treatment faecal egg counts and randomly allocated to different treatment groups. In all studies, cats were treated at the minimum label dose to provide 6.0mg selamectin per kg bodyweight. All animals were euthanized 7-10days after treatment for worm counts. Efficacy was calculated based on the reduction of the geometric mean worm counts in the treated groups versus the placebo-treated control groups. The efficacy against adult hookworms was 99.2%, 94.3% and 100% in three of these studies, and was lower in the remaining two studies. The efficacy against T. cati was 100%. Furthermore, non-interference between sarolaner and selamectin was demonstrated. Thus, a single topical application of the new spot-on formulation of selamectin plus sarolaner at the minimum label dose is effective in the treatment of adult hookworm and roundworm infections in cats.

Topics: Ancylostoma; Ancylostomiasis; Animals; Antiparasitic Agents; Cat Diseases; Cats; Female; Isoxazoles; Ivermectin; Male; Random Allocation; Toxocara; Toxocariasis; Treatment Outcome

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Female; Isoxazoles; Ivermectin; Male; Random Allocation; Tick Infestations; Time Factors; Treatment Outcome

Ticks are increasingly reported on cats worldwide, with Ixodes ricinus being a relevant species across Europe and in near by areas of North Africa and the Middle East. Yet there are few acaracidal products with proven efficacy approved for use in cats. The objective of this study was to compare the efficacy of a new spot-on formulation containing selamectin and sarolaner with a topical application of fluralaner (Bravecto®) against Ixodes ricinus ticks on cats. To that end, twenty-four (24) cats were randomly allocated to one of three treatment groups. The cats in the control group remained untreated. Cats in group 2 were treated with selamectin/sarolaner (Stronghold®Plus; Zoetis) at the minimum recommended dose of 1.0 mg/kg sarolaner and 6.0 mg/kg selamectin on Days 0, 30 and 60. The cats in group 3 received a fluralaner treatment (Bravecto®spot-on solution for cats, MSD) at the minimum recommended dose of 40.0 mg/kg on Day 0. Cats were infested with 50 (± 4) viable, adult, unfed I. ricinus ticks on Days 26, 54, 82 and 89 and ticks were removed for counting 48 h (± 2 h) later.. Three monthly treatments with selamectin/sarolaner provided high and consistent efficacy against I. ricinus for the entire duration of the study period. In contrast, the efficacy of fluralaner declined in the second month after treatment and was below the efficacy threshold of 90% on Days 56, 84 and 91. The percentage efficacy against I. ricinus was numerically higher in the selemectin/sarolaner treated group than in the fluralaner-treated group on Days 56, 84 and 91. Furthermore, greasiness and spiking of the hair, as well as white deposits were frequently observed in the fluralaner-treated cats.. The results of the present study confirm the high and consistent efficacy of a new spot-on combination product containing selamectin and sarolaner against I. ricinus in cats, and indicate a decline in fluralaner efficacy during the 91 day period after treatment.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Azetidines; Cat Diseases; Cats; Drug Therapy, Combination; Female; Isoxazoles; Ivermectin; Ixodes; Male; Spiro Compounds; Tick Infestations

A controlled, blind research study was conducted to define the initial inflammatory response and lung damage associated with the death of immature adult Dirofilaria immitis in cats as compared with cats developing adult heartworm infections and cats on preventive medication.. Three groups of cats were utilized, 10 per group. All cats were infected with 100 third-stage (L3) larvae by subcutaneous injection. Group A cats were treated topically with selamectin (Revolution®; Zoetis) per label directions at 28 days post infection (PI) and once monthly for 8 months. Group B cats were treated orally with ivermectin (Ivomec®; Merial) at 150 μg/kg at 70 days PI, then every 2 weeks for 5 months. Group C cats were untreated PI. At baseline (Day 0) and on Days 70, 110, 168, and 240 PI, peripheral blood, serum, bronchial lavage, and thoracic radiographic images were collected on all cats. Upon completion of the study (Day 245), cats were euthanized and necropsies were conducted.. Results were analyzed statistically between groups by ANOVA and by paired sample T testing for changes within the group over time. The selamectin-treated cats (Group A) did not develop radiographically evident changes throughout the study and were free of adult heartworms or worm fragments at necropsy. The heartworm life cycle was abbreviated with oral doses of ivermectin (Group B), shown by the absence of adult heartworms or worm fragments at necropsy. The early stage of immature adult worm in Group B cats, however, did induce severe pulmonary airway, interstitial, and arterial lung lesions, revealing that the abbreviated infection is a significant cause of respiratory pathology in cats. Cats in Groups B and C could not be differentiated based on radiographic changes, serologic antibody titers, complete blood count, or bronchoalveolar lavage cytology at any time point throughout the study. Eighty percent of cats in Group A and 100% of cats in Groups B and C became heartworm antibody positive at some time point post infection.. The clinical implications of this study are that cats that become infected with immature adult heartworms may not develop fully mature heartworms and are only transiently heartworm antibody positive, but do develop Heartworm-Associated Respiratory Disease (HARD).

Topics: Animals; Antibodies, Helminth; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Female; Filaricides; Ivermectin; Lung; Male; Respiratory Tract Infections

Heartworm-associated respiratory disease (HARD) in cats is induced by the arrival and death of immature adult Dirofilaria immitis in the pulmonary system and is indistinguishable from mature adult heartworm infection.. A controlled, blind research study investigated the long-term (18 months post infection, PI) consequences of the inflammatory response associated with the death of immature adult heartworms in cats. Three groups of cats, 10 per group, were infected with 100 third-stage (L3) larvae by subcutaneous injection. Group A cats were treated with selamectin (Revolution®; Zoetis) per label directions at 28 days PI and once monthly for 17 months. Group B cats were treated orally with ivermectin (Ivomec®; Merial) at 150 μg/kg) at 70 days PI, then every 2 weeks for 15 months. Group C cats were untreated PI. At baseline (Day 0) and on Days 70, 110, 168, 240, 309, 380, and 505 PI, peripheral blood, serum, bronchial lavage, and thoracic radiographic images were collected.. The selamectin-treated cats (Group A) and ivermectin-treated cats (Group B) were free of heartworms or heartworm fragments at necropsy. All cats became heartworm antibody positive at some time point in the study except for one cat in Group A. Only cats in Group C (all with adult heartworms) were heartworm antigen positive. The heartworm antibody titer for Group B was highest on Days 110 to 168 and then decreased over time and 50% were serologically antibody negative on Day 240. Eosinophilic bronchoalveolar lavage (BAL) cytology and peripheral eosinophilia were most pronounced on Day 110 in all cats. Randomly distributed myofibrocytes in the lungs of some Group A cats suggest that precardiac larval stages were affecting the lungs. Radiographs in Group B cats demonstrated partial resolution of the initial HARD reaction but chronic myofibrocyte proliferation was histologically evident 18 months after infection.. HARD was induced by immature adult worm infection with progressive improvement starting 6 to 8 months after infection but histologic lesions were evident in some cats 18 months after infection. The serologic antibody assay was negative in 50% of cats at 8 months and 100% of cats at 18 months post infection. Abnormal radiographic lung patterns continued in a subset of Group B cats for months after heartworm antibody serology and BAL cytology returned to normal.

Topics: Animals; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Disease Progression; Female; Filaricides; Ivermectin; Male; Respiratory Tract Infections; Specific Pathogen-Free Organisms

Bartonella henselae is the causative agent of cat scratch disease in humans, which is recognized as an emerging zoonotic disease. Ctenocephalides felis is the main vector, and transmission of B. henselae infection between cats and humans occurs mainly through infected flea feces. Control of feline infestation with this arthropod vector therefore provides an important strategy for the prevention of infection of both humans and cats. In the present study, a new challenge model is used to evaluate the efficacy of selamectin (Stronghold(®) spot on) in the prevention of B. henselae transmission by C. felis. In this new challenge model, domestic cats were infected by direct application of B. henselae-positive fleas. The fleas used for infestation were infected by feeding on blood that contained in vitro-cultured B. henselae. The direct application of the fleas to the animals and the use of different B. henselae strains ensured a high and consistent challenge. Two groups of six cats were randomly allocated on pre-treatment flea counts to either control (untreated cats) or the selamectin-treated group with one pipette per cat according to the label instruction. Stronghold (selamectin 6 % spot on solution) was administered on days 0 and 32. On days 3, 10, 19, 25, and 31, each cat was infested by direct application of 20 fleas that fed on blood inoculated with B. henselae. Polymerase chain reaction (PCR) on pooled fleas confirmed that the fleas were infected. Blood samples were collected from each cat on days -3 (prior to flea infestation and treatment), 9, 17, 24, 30, 37, and 44 and assayed for B. henselae antibodies using an indirect immunofluorescence (IFA), for the presence of bacteria by bacterial culture and for B. henselae DNA presence by PCR. Cats were also assessed on a daily basis for general health. There were no abnormal health observations during the study and none of the animals required concomitant treatment. None of the cats displayed any clinical signs of bartonellosis during the study. In the untreated group, all cats became bacteremic within 17 to 44 days. None of the selamectin-treated cats became positive during the study. It was concluded that Stronghold(®) spot on administered to cats was efficacious in the prevention of the transmission of B. henselae by fleas to cats in a high-challenge model.

Topics: Angiomatosis, Bacillary; Animals; Antibodies, Bacterial; Antiparasitic Agents; Arthropod Vectors; Bartonella henselae; Cat Diseases; Cats; Ctenocephalides; Flea Infestations; Fluorescent Antibody Technique, Indirect; Humans; Ivermectin; Polymerase Chain Reaction; Zoonoses

A controlled, blind study was conducted to define the initial inflammatory response and lung damage associated with the death of precardiac stages of Dirofilaria immitis in cats as compared to adult heartworm infections and normal cats. Three groups of six cats each were used: UU: uninfected untreated controls; PreS I: infected with 100 D. immitis L3 by subcutaneous injection and treated topically with selamectin 32 and 2 days pre-infection and once monthly for 8 months); IU: infected with 100 D. immitis L3 and left untreated. Peripheral blood, serum, bronchial lavage, and thoracic radiographic images were collected from all cats on Days 0, 70, 110, 168, and 240. CT images were acquired on Days 0, 110, and 240. Cats were euthanized, and necropsies were conducted on Day 240 to determine the presence of heartworms. Bronchial rings were collected for in vitro reactivity. Lung, heart, brain, kidney, and liver tissues were collected for histopathology. Results were compared for changes within each group. Pearson and Spearman correlations were performed for association between histologic, radiographic, serologic, hematologic and bronchoalveolar lavage (BAL) results. Infected cats treated with selamectin did not develop radiographically evident changes throughout the study, were heartworm antibody negative, and were free of adult heartworms and worm fragments at necropsy. Histologic lung scores and CT analysis were not significantly different between PreS I cats and UU controls. Subtle alveolar myofibrosis was noted in isolated areas of several PreS I cats and an eosinophilic BAL cytology was noted on Days 75 and 120. Bronchial ring reactivity was blunted in IU cats but was normal in PreS I and UU cats. The IU cats became antibody positive, and five cats developed adult heartworms. All cats with heartworms were antigen positive at one time point; but one cat was antibody positive, antigen negative, with viable adult females at necropsy. The CT revealed early involvement of all pulmonary arteries and a random pattern of parenchymal disease with severe lesions immediately adjacent to normal areas. Analysis of CT 3D reconstruction and Hounsfield units demonstrated lung disease consistent with restrictive pulmonary fibrosis with an interstitial infiltrate, absence of air trapping, and decrease in total lung volume in Group IU as compared to Groups UU and PreS I. The clinical implications of this study are that cats pretreated with selamectin 1 month before D. immiti

Topics: Animals; Antibodies, Helminth; Antiparasitic Agents; Blood Cell Count; Bronchoalveolar Lavage; Case-Control Studies; Cat Diseases; Cats; Dirofilaria immitis; Echocardiography; Ivermectin; Lung; Lung Diseases; Tomography, X-Ray Computed

The aim of this study was evaluate the efficacy of the use of selamectine in the treatment of O. cynotis in Van Cats.. The material of this study comprised of 30 Van Cat which were infected.. In the clinical examination; restlessness, head shaking, scratching at the ears and wax in both ears with brown-black colored cerumens were found. In the otoscopic examination and analysing the samples, O. cynotis was determined. For treatment, single dose selamectin was given. At the 15th and 30th day after treatment, otoscopic and microscopic examinations were repeated. In the 15th day after the treatment, it was found that clinical symptoms seen in the animals were significantly reduced, only the cerumens in 4 cats remained. Besides, at the 30th day, it is found that all the clinical symptoms disappeared in all animals, and with the otoscopic and microscopic examination it was found that there were no agents of O. cynotis.. As a result, due to the ease of usage in cats housed in a crowd and the reason the efficiency for the treatment used as a single dose, selamectine is efficient for treating O. cynotis in Van Cats and it can be used safely.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Cerumen; Ear; Ear Diseases; Female; Ivermectin; Male; Mite Infestations; Psoroptidae

This case report is presumed to be the first case of infestation of a cat by springtails which are small arthropods closely related to insects. The organisms, found by skin scrapings, were identified as Proisotoma spp. (Collembola: Isotomidae). The cat presented with dermatological lesions (itchy, furfuraceous dermatitis), and we speculate that they were due to this infestation. The pathogenic role of the Collembola was hypothesized because of the large number of organisms, the presence of eggs indicating an active reproduction cycle, the lack of other pathogens (fleas, mites or lice) and the clinical recovery accompanied by the disappearance of Collembola following treatment. The owner seemed to be affected by the infestation, because a few days after having purchased the cat, she developed a pruriginous papular dermatitis on the neck and the arms, which disappeared shortly after treatment of the kitten and a careful washing of all of its toys and other accoutrements.

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Ectoparasitic Infestations; Insecta; Ivermectin; Male

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Humans; Ivermectin; Male; Scabies; Treatment Outcome; United Kingdom; Zoonoses

Neotrombicula autumnalis is the most common species of the family Trombiculidae that parasitizes dogs, cats, and humans in Europe. Besides the skin lesions it may cause, this mite is a possible vector of Anaplasma phagocytophilum and Borrelia burgdorferi sensu lato. Two cases of N. autumnalis infestation in a cat and a dog in the island of Corfu, Greece, and 1 case of infestation in a cat living in Limassol, Cyprus, are presented. To the best or our knowledge, these are the first cases of feline and canine trombiculosis reported in both countries, and their appearance in islands points out to the possibility of introduction through importation of infested dogs and cats. For this reason, parasiticides that are effective for both the treatment and prevention of trombiculosis should be recommended for all dogs and cats that live in areas where the parasite is present as well as for all traveling pets.

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Cyprus; Dog Diseases; Dogs; Female; Greece; Humans; Ivermectin; Larva; Male; Pyrazoles; Treatment Outcome; Trombiculiasis; Trombiculidae

Otodectes cynotis infestation is common in kittens housed in crowded environments like animal shelters. It is unknown how rapidly O cynotis is killed within the first 72h of treatment with currently available products. Kittens ≥4 weeks of age with live O cynotis in both ears (AU) were administered 0.5ml of 0.01% ivermectin otic suspension (Acarexx; Idexx Pharmaceuticals) once, AU or selamectin (Revolution; Pfizer Animal Health) once, on the skin following the manufacturer's instructions. Repeat microscopic examination was performed on individual ears based on a randomization schedule during the 72h after treatment. There was no evidence of toxicity with either drug and administration of 0.01% ivermectin significantly reduced the time to live mite-free status compared to selamectin. Both drugs have an effect against O cynotis as early as 10-12h after administration with an increasing effect over time.

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Ear; Ivermectin; Mite Infestations; Survival Analysis; Treatment Outcome

Two studies were conducted to evaluate and compare the efficacy of imidacloprid + moxidectin and selamectin topical solutions against the KS1 flea strain infesting cats. In both studies the treatment groups were comprised of non-treated controls, 6% w/v selamectin (Revolution®; Pfizer Animal Health) topical solution and 10% w/v imidacloprid + 1% w/v moxidectin (Advantage Multi® for Cats, Bayer Animal Health) topical solution. All cats were infested with 100 fleas on Days -2, 7, 14, 21, and 28. The difference in the studies was that in study #1 efficacy evaluations were conducted at 24 and 48 hours post-treatment or post-infestation, and in study #2 evaluations were conducted at 12 and 24 hours.. In study #1 imidacloprid + moxidectin and the selamectin formulation provided 99.8% and 99.0% efficacy at 24 hours post-treatment. On day 28, the 24 hour efficacy of the selamectin formulation dropped to 87.1%, whereas the imidacloprid + moxidectin formulation provided 98.9% efficacy. At the 48 hour assessments following the 28 day infestations, efficacy of the imidacloprid + moxidectin and selamectin formulations was 96.8% and 98.3% respectively. In study # 2 the efficacy of the imidacloprid + moxidectin and selamectin formulations 12 hours after treatment was 100% and 69.4%, respectively. On day 28, efficacy of the imidacloprid + moxidectin and selamectin formulations 12 hours after infestation was 90.2% and 57.3%, respectively. In study #2 both formulations provided high levels of efficacy at the 24 hour post-infestation assessments, with selamectin and imidacloprid + moxidectin providing 95.3% and 97.5% efficacy, following infestations on day 28.. At the 24 and 48 hour residual efficacy assessments, the imidacloprid + moxidectin and selamectin formulations were similarly highly efficacious. However, the imidacloprid + moxidectin formulation provided a significantly higher rate of flea kill against the KS1 flea strain infesting cats at every 12 hour post-infestation residual efficacy assessment. Both formulations should provide excellent flea control for an entire month on cats.

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Ctenocephalides; Drug Evaluation; Drug Therapy, Combination; Female; Flea Infestations; Imidazoles; Insecticides; Ivermectin; Macrolides; Male; Neonicotinoids; Nitro Compounds; Random Allocation; Treatment Outcome

Otacariasis due to Otodectes cynotis (HERING, 1858) is a very frequent disease of the external ear canal in cats. Otodectes cynotis is the most common mange mite in carnivores. Several antiparasiticides are licensed for treatment. The purpose of this study was to evaluate the efficacy of a formulation containing selamectin (Stronghold(®) Spot-on) for eradication of ear mites in cats under field conditions. Sixteen cats with otacariasis, presented in a small animal clinic, were treated with a single spot-on application of selamectin (Stronghold(®) Spot-on, 6-17.3 mg/kg bdw.). On clinical and parasitological assessment days 14 and 28 clinical signs had subsided in ten cats. Furthermore all ear swabs were negative for mites and their developmental stages on D 14 and D 28. Selamectin was a practical and well-tolerated treatment of feline otacariasis for the cats included in this study. It was very well tolerated in all cats, local skin irritations on the neck did not occur.

Topics: Animals; Antinematodal Agents; Cat Diseases; Cats; Ear Diseases; Ivermectin; Mite Infestations; Treatment Outcome

Four active ingredients--imidacloprid selamectin, fipronil-(S)-methoprene, and metaflumizone--were tested to assess the speed of flea kill against existing flea infestations and subsequent reinfestations. Thirty flea-infested cats were allocated to four treatment groups and one untreated control group. Flea counts were performed 6, 18, and 48 hours after treatment (day 0) and 2, 4, and 24 hours after weekly flea reinfestations. Cats were also reinfested with fleas after the 6- and 18-hour counts on day 0 and after the 2- and 4-hour counts on subsequent count days. Imidacloprid provided significantly greater flea kill at diverse time points. At the 24-hour counts, all compounds showed expected and similar high efficacies. On study day 34, imidacloprid showed the highest efficacy at 24 hours after reinfestation, with 90.8% flea reduction compared with 55.7% to 67.4% in the other treatment groups. A single topical application of imidacloprid provided a high efficacy in the early elimination of adult fleas, limiting the risk of pathogen transmission and flea allergy dermatitis.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Ectoparasitic Infestations; Female; Imidazoles; Insecticides; Ivermectin; Male; Methoprene; Neonicotinoids; Nitro Compounds; Parasite Egg Count; Pyrazoles; Random Allocation; Semicarbazones; Siphonaptera; Time Factors; Treatment Outcome

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Female; Ivermectin; Male; Mite Infestations; Treatment Outcome

Cutaneous nodular dirofilariasis is occasionally reported in dogs but is rare in cats. This report describes two cases of cutaneous nodular lesions due to Dirofilaria immitis adult parasites in domestic shorthaired cats living in an endemic area in northern Italy.

Topics: Administration, Cutaneous; Administration, Oral; Animals; Antigens, Helminth; Cat Diseases; Cats; Diagnosis, Differential; Dirofilaria immitis; Dirofilariasis; Enzyme-Linked Immunosorbent Assay; Female; Filaricides; Italy; Ivermectin; Male

The activity of selamectin, fipronil and imidacloprid against larval cat fleas (Ctenocephalides felis felis) was evaluated in an in vitro potency assay system. One hundred microliters of each compound at various concentrations in acetone were added to glass vials (1.5 by 3 cm) to which had been previously added 20 mg of sand and 10 mg of flea feces. Vials were then ball milled to allow the acetone to evaporate. Selamectin and fipronil were tested at 0.001, 0.003, 0.005, 0.01, 0.03, 0.05, 0.11, 0.3, and 0.5 microg of active compound per tube. Imidacloprid was tested at 0.01, 0.03, 0.05, 0.1, 0.3, 0.5, 1.0, 3.0, and 5.0 microg of active compound per tube. Thirty first instar C. felis larvae were added to each vial. The number of larvae remaining alive in each vial was determined once daily for 72 h. With selamectin, reductions of >/=93.5% were achieved at 24 h after exposure at doses of >/=0.3 microg. In contrast, at 24 h neither fipronil nor imidacloprid reached 90% reduction, even at the highest doses tested (0.5 microg for fipronil and 5.0 microg for imidacloprid). Selamectin was significantly (P/=0.03 microg. A similar pattern of activity was observed at both 48 and 72 h, but higher percentages of larvae were killed for each of the compounds as the incubation time increased. At 72 h selamectin was significantly (P

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Ectoparasitic Infestations; Imidazoles; Ivermectin; Larva; Neonicotinoids; Nitro Compounds; Pyrazoles; Siphonaptera

The purpose of this study was to evaluate the efficacy of a topical formulation of selamectin in the treatment of cheyletiellosis in cats. Fifteen adult domestic cats from the same household with naturally occurring Cheyletiella sp. infestation were enrolled in the study. On each cat, 45 mg of selamectin was applied on days 0, 30, and 60. No other treatment or environmental decontamination was performed during the trial. On days 0, 30, 60, and 120, all cats were examined, epidermal debris was collected over the dorsal area of the body with flea combs for microscopic examination, and fecal flotations were done. Clinical signs had subsided by day 60 in all 15 cats and no signs of recurrence were apparent on follow-up 1 year later. All epidermal and fecal samples were negative by day 60. No adverse reactions were observed. Under the conditions of our study, topical selamectin was a practical and well-tolerated means of treatment for cheyletiellosis in cats.

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Feces; Female; Hair; Humans; Ivermectin; Male; Mite Infestations; Mites; Skin; Time Factors; Treatment Outcome; Zoonoses